Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01089725 · ClinicalTrials.gov registry record · Phase 3
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 385
- Enrollment target
NCT01089725 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 385 participants.
The verdict
NCT01089725, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 385 participants
- Enrollment target
Study Summary
This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will receive an IV infusion and a SC infusion. The study will last 16 weeks for those who wish to enter a 64-week extension study or 24 weeks for those who do not.
Interventions
- BIOLOGICAL Placebo SC
- BIOLOGICAL Placebo IV
- BIOLOGICAL Tanezumab SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2010-03-30 |
| Est. Completion | 2011-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01089725
The ClinicalTrials.gov registry entry for NCT01089725 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo SC is the first listed.
NCT01089725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01089725 about?
NCT01089725 is a clinical study titled "Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study". This is an efficacy and safety study of 3 doses (2.5 mg, 5 mg and 10mg) of tanezumab administered subcutaneously versus placebo. This study will also compare a subcutaneous (SC) administration of 10 mg of tanezumab) with an intravenous (IV) administration of 10 mg of tanezumab. Each person will rece...
What is the current status of trial NCT01089725?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 385 participants. The study started on 2010-03-30. Estimated completion is 2011-02-18.
What interventions are being tested in trial NCT01089725?
The interventions under investigation include: Placebo SC (BIOLOGICAL), Placebo IV (BIOLOGICAL), Tanezumab SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01089725?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.